Advertisement

Lipoprotein(a) variability over time in adult lipid clinic patients

  • Isabel Shamsudeen
    Affiliations
    Department of Medicine, Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street North, London, Ontario, N6A 5B7, Canada
    Search for articles by this author
  • Robert A. Hegele
    Correspondence
    Corresponding author. Robarts Research Institute, Western University, 4288A-1151 Richmond Street North, London, ON, N6A 5B7, Canada.
    Affiliations
    Department of Medicine, Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street North, London, Ontario, N6A 5B7, Canada
    Search for articles by this author
      Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL)-like particle in which apolipoprotein (apo) B is covalently bound to a plasminogen-like molecule called apo(a) [
      • Langsted A.
      • Nordestgaard B.G.
      Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?.
      ]. Elevated plasma Lp(a) concentration is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, stroke and cardiac death [
      • Langsted A.
      • Nordestgaard B.G.
      Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?.
      ]. The European Atherosclerosis Society, European Society of Cardiology and Canadian Cardiovascular Society (CCS) dyslipidemia guidelines recommend measurement of Lp(a) once in an individual's lifetime to identify patients with high levels who would benefit from earlier, more intensive health behaviour modification and management of ASCVD risk [
      • Mach F.
      • Baigent C.
      • Catapano A.L.
      • Koskinas K.C.
      • Casula M.
      • et al.
      ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
      ,
      • Pearson G.J.
      • Thanassoulis G.
      • Anderson T.J.
      • Barry A.R.
      • Couture P.
      • et al.
      Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.
      ]. The recommendation of a single measurement is based on the concept that Lp(a) is genetically determined and remains stable over an individual's lifetime [
      • Cegla J.
      • France M.
      • Marcovina S.M.
      • Neely R.D.
      Lp (a): when and how to measure it.
      ]. However, literature evidence on the long term stability of Lp(a) concentrations in adults is sparse.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Langsted A.
        • Nordestgaard B.G.
        Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?.
        Curr. Opin. Lipidol. 2020; 31: 125-131
        • Mach F.
        • Baigent C.
        • Catapano A.L.
        • Koskinas K.C.
        • Casula M.
        • et al.
        ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
        Eur. Heart J. 2019; 41 (2020): 111-188
        • Pearson G.J.
        • Thanassoulis G.
        • Anderson T.J.
        • Barry A.R.
        • Couture P.
        • et al.
        Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.
        Can. J. Cardiol. 2021; 37 (2021): 1129-1150
        • Cegla J.
        • France M.
        • Marcovina S.M.
        • Neely R.D.
        Lp (a): when and how to measure it.
        Ann. Clin. Biochem. 2021; 58: 16-21
        • de Boer L.M.
        • Hof M.H.
        • Wiegman A.
        • Stroobants A.K.
        • Kastelein J.J.
        • et al.
        Lipoprotein (a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic.
        Atherosclerosis. 2022; 349: 227-232
        • Trinder M.
        • Paruchuri K.
        • Haidermota S.
        • Bernardo R.
        • Zekavat S.M.
        • et al.
        Repeat measures of Lipoprotein(a) molar concentration and cardiovascular risk.
        J. Am. Coll. Cardiol. 2022; 79: 617-628
        • Marcovina S.M.
        • Viney N.J.
        • Hughes S.G.
        • Xia S.
        • Witztum J.L.
        • et al.
        Temporal variability in lipoprotein (a) levels in patients enrolled in the placebo arms of IONIS-APO (a) Rx and IONISAPO (a)-LRx antisense oligonucleotide clinical trials.
        J Clin Lipidol. 2018; 12: 122-129